Tolebrutinib Trials Paused Over Safety Concerns & Setback for MS Spasticity Treatment

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how new U.S. enrollments in Phase 3 trials of tolebrutinib for MS have been paused due to some reports of liver injury.

He also reads “Trial Results a Setback for US Approval of Nabiximols for MS Spasticity” from Ed Tobias’ column “The MS Wire.”

===================================

Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/

=====================================

To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/